Hepatitis B virus surface antigen seroconversion in HIV-infected individual after pegylated interferon-alpha treatment: a case report

Hepatitis B virus surface antigen seroconversion in HIV-infected individual after pegylated interferon-alpha treatment: a case report

Hepatitis B virus (HBV) infects from 6 to 14% of HIV-infected individuals. Concurrent HIV/HBV infection occurs due to the overlapping routes of transmission, particularly sexual and parenteral. HIV-infected patients that have acute hepatitis B have six times greater risk of developing chronic hepati...

Full description

Bibliographic Details
Main Authors:	Adriane Maira Delicio, Paulo Afonso Martins Abati, Aline Gonzalez Vigani
Format:	Article
Language:	English
Published:	SciELO 2013-12-01
Series:	Journal of Venomous Animals and Toxins including Tropical Diseases
Subjects:	HIV Hepatitis B HBsAg Peginterferon
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1678-91992013000100503&lng=en&tlng=en

Similar Items

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials
by: Zhang Yu-guo, et al.
Published: (2011-06-01)

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy
by: Kanako Yoshida, et al.
Published: (2021-02-01)

Prediction for HBsAg seroconversion in children with chronic hepatitis B
by: Yan-Wei Zhong, et al.
Published: (2021-12-01)

Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens
by: Fengping Wu, et al.
Published: (2023-01-01)

Response predictors to treatment with pegylated interferon in chronic hepatitis B
by: Paulo Roberto Abrão Ferreira, et al.

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
by: Hong Li, et al.
Published: (2022-12-01)

Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers
by: Hong Li, et al.
Published: (2022-04-01)

Age-wise and Gender-wise Prevalence of Hepatitis B Virus (HBV) Infection in Lahore, Pakistan
by: Aqib Nazeer, et al.
Published: (2019-12-01)

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
by: Yan L, et al.
Published: (2018-10-01)

Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B
by: I-Cheng Lee, et al.
Published: (2021-09-01)

Analytical Performance of the Sysmex HISCL HBsAg Assay and Comparison with the Roche Elecsys HBsAg II Quant Assay in the Quantification of Hepatitis B Surface Antigen
by: Joonhong Park, et al.
Published: (2021-11-01)

Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir
by: Guei-Ying Chen, et al.
Published: (2015-11-01)

Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B
by: Zhan-Qing Zhang, et al.
Published: (2017-12-01)

Comparative ELISA reagents for detection of hepatitis B surface antigen (HBsAg) Comparação de reativos para o teste de ELISA na evidenciação do antígeno de superfície de hepatite B
by: I. F. Camargo, et al.
Published: (1987-06-01)

A comparison on HBsAg and HBsAb prevalence in patients with Down syndrome and other mentally retarded patients living in retarded children institutes in Tehran
by: Sahebjamei M. Associate Professor, et al.
Published: (2003-06-01)

Seroprevalence of Hepatitis B virus Infection by Quantitative Chemiluminescent in Tabriz (North West of Iran), 2010-2011
by: Nader Hajizadeh, et al.
Published: (2014-08-01)

Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA)
by: Carla S. Coffin, et al.
Published: (2022-11-01)

Status of Hepatitis Be Antigen in Chronic Hepatitis B Patients from Various Regions of Pakistan
by: Agha Babar Hussain
Published: (2017-09-01)

Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B
by: Li H, et al.
Published: (2018-05-01)

Seromarkers of Hepatitis B virus in newborns with HBsAg positive mothers
by: Yousef Yahyapour (PhD), et al.
Published: (2009-05-01)

Prevalencia de anticuerpos anti-VHC y del antígeno de superficie de la hepatitis B en pacientes tratados con hemodiálisis Prevalence of anti-HCV antibodies and of the hepatitis B surface antigen in patients treated with hemodialysis
by: Zuzet Martínez Córdova, et al.
Published: (2008-03-01)

Clinical study of hepatitis B vaccine in achieving hepatitis B surface antibody seroconversion in patients with functional cure
by: Yisi Liu, et al.
Published: (2023-11-01)

Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis
by: Aixin Song, et al.
Published: (2021-11-01)

Expression and purification of hepatitis B surface antigen S from <it>Escherichia coli</it>; a new simple method
by: Elghanam Mohamed S, et al.
Published: (2012-03-01)

Seroprevalence of hepatitis B surface antigen and its correlation with risk factors among new recruits in Turkey
by: Tulin Altay, et al.

Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
by: Ekta Gupta, et al.
Published: (2023-12-01)

Detecting Hepatitis B Surface Antigen Mutants
by: Paul F. Coleman
Published: (2006-02-01)

Occult hepatitis B virus infection: clearance or disguise?
by: Jin-Wook Kim
Published: (2014-09-01)

Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: A real-world data from Electronic Health Record
by: Zongqi Shi, et al.
Published: (2023-05-01)

HBsAg in Cord Blood Qf Newborns of HBsAg-Positive Mothers
by: Adnan S. Wiharta, et al.
Published: (2018-11-01)

Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies
by: Lorenzo Piermatteo, et al.
Published: (2023-12-01)

Sero-prevalence of Hepatitis B Virus infection in Balochistan province of Pakistan
by: Nadeem S Sheikh, et al.
Published: (2011-01-01)

Evolution of hepatitis B virus surface gene and protein among Iranian chronic carriers from different provinces
by: Fatemeh Ramezani, et al.
Published: (2015-11-01)

An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression
by: Giuseppina Brancaccio, et al.
Published: (2021-04-01)

Evaluación serológica de la inmunización pasiva-activa en la profilaxis de la transmisión perinatal de la hepatitis B
by: Marité Bello, et al.
Published: (2012-04-01)

Evaluating the Immunity against Hepatitis B Virus and Frequency of HBsAg Positive Cases among Medical Staff of Shahid Beheshti Hospital in Yasuj, 2016
by: MT Rezanejad, et al.
Published: (2017-12-01)

Protection against hepatitis B by the Butang® recombinant vaccine in newborn children in South Brazil
by: Aline Paula Isolani, et al.
Published: (2006-08-01)

Accuracy Validation of the Elecsys HBsAg II Quant Assay and Its Utility in Resolving Equivocal Qualitative HBsAg Results
by: Jaehyeon Lee, et al.
Published: (2023-02-01)

Seroprevalence of hepatitis B surface antigen (HBsAg) in Bo, Sierra Leone, 2012–2013
by: Rashid Ansumana, et al.
Published: (2018-02-01)

Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B: A multicentre cohort study
by: Milan J. Sonneveld, et al.
Published: (2023-08-01)